{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:59:12Z","timestamp":1793703552971,"version":"4.5.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012276","name":"Tillotts Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019551","name":"Seres Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012009","name":"United Soybean Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017077","name":"Hospira","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021560","name":"Atlantic Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1053\/j.gastro.2019.06.038","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T11:06:03Z","timestamp":1562238363000},"page":"1007-1018.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":206,"title":["Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn\u2019s Disease"],"prefix":"10.1053","volume":"157","author":[{"given":"Silvio","family":"Danese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1814-4198","authenticated-orcid":false,"given":"Jordi","family":"Rimola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenifer","family":"Siegelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2019.06.038_bib1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1159\/000338137","article-title":"How to guide therapeutic decisions in a patient-tailored approach to treatment of IBD?","volume":"30","author":"Rutgeerts","year":"2012","journal-title":"Dig Dis"},{"key":"10.1053\/j.gastro.2019.06.038_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.gastro.2016.12.004","article-title":"Inflammatory bowel disease 2017: innovations and changing paradigms","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management strategies to improve outcomes of patients with inflammatory bowel diseases","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2014.09.015","article-title":"Development of the Lemann index to assess digestive tract damage in patients with Crohn's disease","volume":"148","author":"Pariente","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib5","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2019.06.038_bib6","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2019.06.038_bib7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.cgh.2018.02.051","article-title":"Heterogeneity in definitions of efficacy and safety endpoints for clinical trials of Crohn's disease: a systematic review for development of a core outcome set","volume":"16","author":"Ma","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2019.06.038_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.crohns.2013.09.016","article-title":"European evidence based consensus for endoscopy in inflammatory bowel disease","volume":"7","author":"Annese","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2019.06.038_bib9","series-title":"Advances in endoscopy in inflammatory bowel disease","first-page":"193","article-title":"The efficacies and issues for endoscopic assessment of mucosal healing in patients with Crohn\u2019s disease","author":"Watanabe","year":"2018"},{"key":"10.1053\/j.gastro.2019.06.038_bib10","first-page":"CD010642","article-title":"Endoscopic scoring indices for evaluation of disease activity in Crohn's disease","volume":"8","author":"Khanna","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2019.06.038_bib11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/ecco-jcc\/jjy097","article-title":"VIEWPOINT: Defining endoscopic remission in ileocolonic Crohn's disease: let's start from scratch","volume":"12","author":"Bossuyt","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2019.06.038_bib12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/apt.15250","article-title":"Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease","volume":"49","author":"Novak","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2019.06.038_bib13","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.gie.2018.08.018","article-title":"The emerging role of histologic disease activity assessment in ulcerative colitis","volume":"88","author":"Pai","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"10.1053\/j.gastro.2019.06.038_bib14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1053\/j.gastro.2019.06.038_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2019.06.038_bib16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"issue":"supplement_1","key":"10.1053\/j.gastro.2019.06.038_bib17","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1093\/ecco-jcc\/jjx180.503","article-title":"P376 Clinical effectiveness of vedolizumab in a tertiary care cohort of IBD patients","volume":"12","author":"Bots","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"issue":"supplement_1","key":"10.1053\/j.gastro.2019.06.038_bib18","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/ecco-jcc\/jjx180.645","article-title":"P518 Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease","volume":"12","author":"Chao","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2019.06.038_bib19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY Consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"supplement_1","key":"10.1053\/j.gastro.2019.06.038_bib20","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1093\/ecco-jcc\/jjx180.674","article-title":"P547 Clinical effectiveness of vedolizumab: interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)","volume":"12","author":"Eriksson","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"issue":"supplement_1","key":"10.1053\/j.gastro.2019.06.038_bib21","doi-asserted-by":"crossref","first-page":"S029","DOI":"10.1093\/ecco-jcc\/jjx180.038","article-title":"DOP001 Effectiveness and safety of vedolizumab in anti-TNF na\u00efve patients with inflammatory bowel disease: a multicentre retrospective European Crohn\u2019s and Colitis Organisation study","volume":"12","author":"Kopylov","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2019.06.038_bib22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/apt.14919","article-title":"Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease","volume":"48","author":"Kotze","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2019.06.038_bib23","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.05.067","article-title":"Vedolizumab induces endoscopic and histological remission in\u00a0patients with Crohn's disease","author":"Lowenberg","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib24","first-page":"A173","article-title":"Defining and validating cut-offs for the Simple Endoscopic Score for Crohn's disease","volume":"132","author":"Moskovitz","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib25","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/ibd.21300","article-title":"Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD","volume":"16","author":"Sipponen","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2019.06.038_bib26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/gut.2008.167957","article-title":"Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease","volume":"58","author":"Rimola","year":"2009","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2019.06.038_bib27","first-page":"CD012351","article-title":"Histologic scoring indices for evaluation of disease activity in Crohn\u2019s disease","volume":"7","author":"Novak","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2019.06.038_bib28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib29","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A\u00a0new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1053\/j.gastro.2019.06.038_bib31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"10.1053\/j.gastro.2019.06.038_bib32","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","article-title":"Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn's disease","volume":"155","author":"Rutgeerts","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib34","first-page":"425","article-title":"Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease: results from the EXTEND trial","volume":"11","author":"Reinisch","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2019.06.038_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should we divide Crohn's disease into ileum-dominant and isolated colonic diseases","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2019.06.038_bib36","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2019.06.038_bib37","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2019.06.038_bib38","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/ibd.21551","article-title":"Magnetic resonance imaging for evaluation of Crohn\u2019s disease: validation of parameters of severity and quantitative index of activity","volume":"17","author":"Rimola","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2019.06.038_bib39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/ajg.2013.385","article-title":"Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn's disease: validation of quantitative index of activity","volume":"109","author":"Hordonneau","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2019.06.038_bib40","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1097\/MIB.0000000000000449","article-title":"Correlation of the endoscopic and magnetic resonance scoring systems in the deep small intestine in Crohn\u2019s disease","volume":"21","author":"Takenaka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2019.06.038_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/apt.13453","article-title":"Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn\u2019s disease, and may help select subjects with active inflammation","volume":"43","author":"Coimbra","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2019.06.038_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12880-016-0139-7","article-title":"Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn\u2019s disease: correlation with SES-CD and clinical-biological markers","volume":"16","author":"Stoppino","year":"2016","journal-title":"BMC Med Imaging"},{"key":"10.1053\/j.gastro.2019.06.038_bib43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00535-016-1253-6","article-title":"Comparison of three magnetic resonance enterography indices for grading activity in Crohn\u2019s disease","volume":"52","author":"Rimola","year":"2017","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2019.06.038_bib44","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.crohns.2014.08.011","article-title":"Systematic review: histological remission in inflammatory bowel disease. Is \u2018complete\u2019 remission the new treatment paradigm? An IOIBD initiative","volume":"8","author":"Bryant","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2019.06.038_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2019.06.038_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","article-title":"Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials","volume":"13","author":"Feagan","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2019.06.038_bib47","first-page":"A173","article-title":"Defining and validating cut-offs for the Simple Endoscopic Score for Crohn's disease","volume":"132","author":"Moskovitz","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib48","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/ibd.21300","article-title":"Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD","volume":"16","author":"Sipponen","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2019.06.038_bib49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.gastro.2013.10.055","article-title":"Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease","volume":"146","author":"Ordas","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2019.06.038_bib50","first-page":"CD012351","article-title":"Histologic scoring indices for evaluation of disease activity in Crohn\u2019s disease","volume":"7","author":"Novak","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508519410809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508519410809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:44:48Z","timestamp":1762163088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508519410809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0016508519410809"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2019.06.038","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2019.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}